x-tosis lands a $2.74M Michael J. Fox Foundation grant to push XTS001, a brain-penetrant VDAC1-oligomerization blocker, toward Parkinson's

On June 23, 2026, x-tosis announced a $2.74 million grant from The Michael J. Fox Foundation for Parkinson's Research, awarded through its Parkinson's Disease Therapeutics Pipeline Program. The funding advances XTS001, the company's lead candidate, toward clinical development.

XTS001 is a brain-penetrant, orally available small molecule designed to inhibit VDAC1 oligomerization, the process by which VDAC1 clumps into a large pore that leaks mtDNA, triggers inflammation, and contributes to neuron death. It comes off the company's MitoXTS™ platform of patented VDAC1-oligomerization inhibitors, building on 50+ years of work by Professor Varda Shoshan-Barmatz in the same lineage as the VBIT compounds. In preclinical Parkinson's models, x-tosis reports XTS001 reduced dopaminergic neuron loss and helped restore dopamine levels.

It is a concrete test of the mechanism this site covers, aimed at a disease where energy-starved neurons die, now with a foundation grant behind it.